Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment

Rheumatol Int. 2009 Dec;30(2):275-6. doi: 10.1007/s00296-009-0931-6.

Abstract

Tumor necrosis factor (TNF)-α inhibitors are increasingly being used to treat rheumatoid arthritis. Infliximab (INF) is a TNF-α inhibitor that is usually used in combination with methotrexate (MTX). Interstitial lung disease (ILD) during combination therapy has been attributed to MTX rather than INF. However, INF-associated ILD without combination with MTX has recently been reported. We describe herein a case of severe ILD secondary to INF without MTX therapy.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy*
  • Azathioprine / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Humans
  • Infliximab
  • Lung Diseases, Interstitial / diagnostic imaging
  • Lung Diseases, Interstitial / etiology*
  • Methotrexate / therapeutic use
  • Methylprednisolone / therapeutic use
  • Mucin-1 / blood
  • Radiography
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • MUC1 protein, human
  • Mucin-1
  • Infliximab
  • Azathioprine
  • Methylprednisolone
  • Methotrexate